healthequity inc - HQY
HQY
Close Chg Chg %
83.38 1.29 1.55%
Closed Market
84.67
+1.29 (1.55%)
Volume: 640.30K
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: healthequity inc - HQY
HQY Key Data
| Open $83.22 | Day Range 81.92 - 85.09 |
| 52 Week Range 72.76 - 116.65 | Market Cap $7.15B |
| Shares Outstanding 84.48M | Public Float 82.46M |
| Beta 0.26 | Rev. Per Employee N/A |
| P/E Ratio 34.42 | EPS $2.50 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 977.18K |
HQY Performance
| 1 Week | 2.62% | ||
| 1 Month | 8.05% | ||
| 3 Months | -7.03% | ||
| 1 Year | 7.45% | ||
| 5 Years | 24.31% |
HQY Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
17
Full Ratings ➔
About healthequity inc - HQY
HealthEquity, Inc. engages in the provision of technology-enabled services for healthcare and spending decisions. The company was founded by Stephen D. Neeleman on September 18, 2002 and is headquartered in Draper, UT.
HQY At a Glance
HealthEquity, Inc.
15 West Scenic Pointe Drive
Draper, Utah 84020
| Phone | 1-801-727-1000 | Revenue | 1.31B | |
| Industry | Investment Managers | Net Income | 215.20M | |
| Sector | Finance | 2026 Sales Growth | 9.473% | |
| Fiscal Year-end | 01 / 2027 | Employees | 2,814 | |
| View SEC Filings |
HQY Valuation
| P/E Current | 34.416 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 34.822 |
| Price to Sales Ratio | 5.706 |
| Price to Book Ratio | 3.456 |
| Price to Cash Flow Ratio | 16.39 |
| Enterprise Value to EBITDA | 16.959 |
| Enterprise Value to Sales | 6.225 |
| Total Debt to Enterprise Value | 0.122 |
HQY Efficiency
| Revenue/Employee | 466,748.045 |
| Income Per Employee | 76,475.124 |
| Receivables Turnover | 10.618 |
| Total Asset Turnover | 0.377 |
HQY Liquidity
| Current Ratio | 3.266 |
| Quick Ratio | 3.266 |
| Cash Ratio | 2.033 |
HQY Profitability
| Gross Margin | 61.302 |
| Operating Margin | 24.933 |
| Pretax Margin | 21.123 |
| Net Margin | 16.385 |
| Return on Assets | 6.17 |
| Return on Equity | 10.194 |
| Return on Total Capital | 6.923 |
| Return on Invested Capital | 6.819 |
HQY Capital Structure
| Total Debt to Total Equity | 47.527 |
| Total Debt to Total Capital | 32.216 |
| Total Debt to Total Assets | 29.18 |
| Long-Term Debt to Equity | 47.056 |
| Long-Term Debt to Total Capital | 31.897 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Healthequity Inc - HQY
Collapse All in section
| All values USD millions. | 2023 | 2024 | 2025 | 2026 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 861.75M | 999.59M | 1.20B | 1.31B | |
Sales Growth
| +13.90% | +16.00% | +20.03% | +9.47% | |
Cost of Goods Sold (COGS) incl D&A
| 466.24M | 469.71M | 507.19M | 508.27M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 161.20M | 153.08M | 162.45M | 154.66M | |
Depreciation
| 12.30M | 8.80M | 4.60M | 2.00M | |
Amortization of Intangibles
| 148.90M | 144.28M | 157.85M | 152.66M | |
COGS Growth
| +12.17% | +0.74% | +7.98% | +0.21% | |
Gross Income
| 395.50M | 529.87M | 692.58M | 805.16M | |
Gross Income Growth
| +16.01% | +33.97% | +30.71% | +16.26% | |
Gross Profit Margin
| +45.90% | +53.01% | +57.73% | +61.30% |
| 2023 | 2024 | 2025 | 2026 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 357.85M | 401.74M | 462.51M | 477.68M | |
Research & Development
| 193.38M | 218.81M | 239.51M | 262.51M | |
Other SG&A
| 164.48M | 182.93M | 223.00M | 215.17M | |
SGA Growth
| +19.15% | +12.26% | +15.13% | +3.28% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 28.65M | 11.59M | 69.31M | 5.02M | |
EBIT after Unusual Expense
| 9.00M | 116.54M | 160.76M | 322.46M | |
Non Operating Income/Expense
| 1.32M | 12.80M | 14.33M | 12.11M | |
Non-Operating Interest Income
| 1.76M | 12.14M | 13.91M | 11.73M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 48.42M | 54.30M | 59.06M | 57.13M | |
Interest Expense Growth
| +48.89% | +12.13% | +8.77% | -3.26% | |
Gross Interest Expense
| 48.42M | 54.30M | 59.06M | 57.13M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (38.10M) | 75.04M | 116.03M | 277.43M | |
Pretax Income Growth
| +42.92% | +296.98% | +54.63% | +139.10% | |
Pretax Margin
| -4.42% | +7.51% | +9.67% | +21.12% | |
Income Tax
| (11.95M) | 19.33M | 19.33M | 62.23M | |
Income Tax - Current - Domestic
| 5.23M | 33.32M | 32.16M | 22.47M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (17.18M) | (13.99M) | (12.83M) | 39.76M | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (26.14M) | 55.71M | 96.70M | 215.20M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (26.14M) | 55.71M | 96.70M | 215.20M | |
Net Income Growth
| +40.97% | +313.10% | +73.58% | +122.54% | |
Net Margin Growth
| -3.03% | +5.57% | +8.06% | +16.38% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (26.14M) | 55.71M | 96.70M | 215.20M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (26.14M) | 55.71M | 96.70M | 215.20M | |
EPS (Basic)
| -0.3096 | 0.6511 | 1.1132 | 2.4985 | |
EPS (Basic) Growth
| +41.88% | +310.30% | +70.97% | +124.44% | |
Basic Shares Outstanding
| 84.44M | 85.56M | 86.87M | 86.13M | |
EPS (Diluted)
| -0.3096 | 0.6407 | 1.0886 | 2.4602 | |
EPS (Diluted) Growth
| +41.88% | +306.94% | +69.91% | +126.00% | |
Diluted Shares Outstanding
| 84.44M | 86.96M | 88.83M | 87.47M | |
EBITDA
| 198.85M | 281.21M | 392.52M | 482.14M | |
EBITDA Growth
| +11.87% | +41.42% | +39.58% | +22.83% | |
EBITDA Margin
| +23.08% | +28.13% | +32.72% | +36.71% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 111.625 | |
| Number of Ratings | 17 | Current Quarters Estimate | 1.113 | |
| FY Report Date | 04 / 2026 | Current Year's Estimate | 4.623 | |
| Last Quarter’s Earnings | 0.95 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 4.00 | Next Fiscal Year Estimate | 5.337 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 15 | 15 | 15 | 14 |
| Mean Estimate | 1.11 | 1.19 | 4.62 | 5.34 |
| High Estimates | 1.14 | 1.25 | 4.73 | 5.98 |
| Low Estimate | 1.05 | 1.14 | 4.55 | 5.10 |
| Coefficient of Variance | 2.21 | 3.16 | 1.06 | 4.32 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 13 | 13 |
| OVERWEIGHT | 2 | 2 | 2 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Healthequity Inc - HQY
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Healthequity Inc - HQY
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Sep 10, 2025 | Evelyn S. Dilsaver Director | 51,669 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $21.27 per share | 1,098,999.63 |
| Sep 10, 2025 | Evelyn S. Dilsaver Director | 48,208 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $93.3 per share | 4,497,806.40 |
| Sep 10, 2025 | Evelyn S. Dilsaver Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 1, 2025 | Stephen D. Neeleman FOUNDER AND VICE CHAIRMAN; Director | 550,235 | Bona fide gift | 0.00 |
| Jul 9, 2025 | Michael Fiore EVP, CHIEF COMMERCIAL OFFICER | 53,225 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $102.09 per share | 5,433,740.25 |
| Jul 9, 2025 | Michael Fiore EVP, CHIEF COMMERCIAL OFFICER | 53,925 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $101.5 per share | 5,473,387.50 |
| Jul 9, 2025 | Michael Fiore EVP, CHIEF COMMERCIAL OFFICER | 55,019 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.87 per share | 5,549,766.53 |
| Jul 9, 2025 | Elimelech Rosner EVP, CHIEF TECHNOLOGY OFFICER | 59,707 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.87 per share | 6,022,645.09 |
| Jul 9, 2025 | Delano Ladd EVP, General Counsel | 85,456 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.87 per share | 8,619,946.72 |
| Jul 9, 2025 | James M. Lucania EVP & CFO | 89,429 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.87 per share | 9,020,703.23 |
| Jul 9, 2025 | Stephen D. Neeleman FOUNDER AND VICE CHAIRMAN; Director | 112,593 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.87 per share | 11,357,255.91 |
| Jun 11, 2025 | Elimelech Rosner EVP, CHIEF TECHNOLOGY OFFICER | 62,689 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $111.37 per share | 6,981,673.93 |
| Apr 7, 2025 | Scott R. Cutler President and CEO; Director | 122,316 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 7, 2025 | James M. Lucania EVP & CFO | 91,804 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $83.88 per share | 7,700,519.52 |
| Apr 7, 2025 | Delano Ladd EVP, General Counsel | 94,769 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 7, 2025 | Delano Ladd EVP, General Counsel | 93,417 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $83.88 per share | 7,835,817.96 |
| Apr 7, 2025 | Elimelech Rosner EVP, CHIEF TECHNOLOGY OFFICER | 185,767 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $83.88 per share | 15,582,135.96 |
| Apr 7, 2025 | Stephen D. Neeleman FOUNDER AND VICE CHAIRMAN; Director | 122,661 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $83.88 per share | 10,288,804.68 |
| Apr 7, 2025 | Jon Kessler Director | 409,557 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |